We are live on ! Find out more
CSTL icon

Castle Biosciences
CSTL

67 hedge funds and large institutions have $176M invested in Castle Biosciences in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 8

133% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 12

99% more capital invested

Capital invested by funds: $88.1M → $176M (+$87.5M)

18% more funds holding

Funds holding: 57 → 67 (+10)

1.4% more ownership

Funds ownership: 28.52% → 29.93% (+1.4%)

Holders
67
Holders Change
+10
Holders Change %
+17.54%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
23
Increased
28
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.58M
2
PCM
Portolan Capital Management
Massachusetts
+$4.42M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$4.36M
4
WA
Wasatch Advisors
Utah
+$2.47M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.14M

Top Sellers

Rank Fund Capital Flow
1
NAM
Nexpoint Asset Management
Texas
-$7.92M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$4.07M
3
Millennium Management
Millennium Management
New York
-$2.81M
4
RI
RTW Investments
New York
-$2.79M
5
PVI
Pura Vida Investments
New York
-$2.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
GPGA
26
Grandeur Peak Global Advisors
Utah
$1.11M -$1.15M -47,150 -59%
PCM
27
Perkins Capital Management
Minnesota
$942K -$12.8K -525 -2%
BIM
28
Bogle Investment Management
Massachusetts
$937K +$667K +27,260 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$900K +$640K +26,186 New
PCM
30
Prelude Capital Management
New York
$828K – – –
FAM
31
Fred Alger Management
New York
$756K +$48.9K +2,000 +10%
Ensign Peak Advisors
32
Ensign Peak Advisors
Utah
$699K +$498K +20,351 New
CIP
33
Chartwell Investment Partners
Pennsylvania
$645K -$450K -18,400 -50%
Morgan Stanley
34
Morgan Stanley
New York
$555K +$310K +12,689 +367%
S
35
SignatureFD
Georgia
$554K +$394K +16,132 New
Alyeska Investment Group
36
Alyeska Investment Group
Illinois
$551K -$4.07M -166,254 -91%
MFIM
37
Mesirow Financial Investment Management
Illinois
$531K +$378K +15,463 New
Two Sigma Advisers
38
Two Sigma Advisers
New York
$495K -$48.9K -2,000 -12%
PPA
39
Parametric Portfolio Associates
Washington
$382K +$8.56K +350 +3%
Charles Schwab
40
Charles Schwab
California
$356K +$253K +10,335 New
MPAM
41
Monarch Partners Asset Management
Massachusetts
$350K -$157K -6,420 -39%
Citadel Advisors
42
Citadel Advisors
Florida
$305K -$532K -21,775 -71%
SEI Investments
43
SEI Investments
Pennsylvania
$272K +$193K +7,909 New
Wells Fargo
44
Wells Fargo
California
$210K +$61.4K +2,510 +70%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$193K -$3.59K -147 -3%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$189K +$134K +5,500 New
UBS Group
47
UBS Group
Switzerland
$178K +$58.3K +2,383 +85%
Bank of America
48
Bank of America
North Carolina
$150K +$63.7K +2,604 +148%
TRCT
49
Tower Research Capital (TRC)
New York
$85K +$60.5K +2,476 New
AIG
50
American International Group
New York
$82K +$978 +40 +2%
1
2
3

CSTL Hedge Fund Activity: Q4 2019 in Review

67 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2019, worth a combined $176M — up 99% from $88.1M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CSTL positions and 8 closed out — a net gain of 15 holders — while 28 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $5.58M. The largest seller was Nexpoint Asset Management, cutting an estimated $7.92M.

  • 67 institutional investors held Castle Biosciences (CSTL) as of Q4 2019, up from 57 in Q3 2019.
  • Funds reported $176M of Castle Biosciences stock for Q4 2019, up 99% quarter-over-quarter.
  • 23 funds opened new Castle Biosciences positions in Q4 2019 and 8 closed out, a net change of +15 holders.
  • The largest Castle Biosciences buyer in Q4 2019 was BlackRock, an estimated $5.58M added.
  • The largest Castle Biosciences seller in Q4 2019 was Nexpoint Asset Management, an estimated $7.92M sold.

Based on aggregated 13F filings for Q4 2019.